Cargando…
1839. Impact of Hypoalbuminemia on Ceftriaxone Treatment Failure in Patients With Enterobacterales Bacteremia
BACKGROUND: Ceftriaxone (CRO) is a third-generation cephalosporin that is commonly prescribed due to its robust Gram-negative activity and lack of renal dose adjustments. It is also highly protein bound allowing for once daily dosing. In patients with hypoalbuminemia, however, the proportion of free...
Autores principales: | Steere, Evan, Eubank, Taryn, Greenlee, Sage, Cooper, Megan, Drake, Ty C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752600/ http://dx.doi.org/10.1093/ofid/ofac492.1468 |
Ejemplares similares
-
Impact of Hypoalbuminemia on Ceftriaxone Treatment Failure in Patients With Enterobacterales Bacteremia: A Propensity-Matched, Retrospective Cohort Study
por: Steere, Evan L, et al.
Publicado: (2023) -
2527. Impact of Hypoalbuminemia on Clinical Outcomes Among Patients with Obesity Treated with Ceftriaxone
por: Rivera (O'Connor), Christina G, et al.
Publicado: (2023) -
2262. Evaluation of Ceftriaxone Versus Cefazolin as a Surrogate Marker for Cefpodoxime Susceptibility in Enterobacterales Isolates
por: Lambert, Kaitlyn, et al.
Publicado: (2023) -
2776. Decrease in ceftriaxone treatment failure rates for infections caused by inducible AmpC producing Enterobacterales associated with changes in laboratory susceptibility testing reporting
por: Khan, Ayesha, et al.
Publicado: (2023) -
602. Clinical Outcomes of Ertapenem in Patients with Hypoalbuminemia
por: Gavaghan, Victoria, et al.
Publicado: (2022)